

EGFR+, ALK+ and ROS1+ NSCLC: More options, right choices

Monday 30th September 2019, 13:00–14:30

Tarragona Auditorium, Hall 7, Fira Gran Via, Barcelona, Spain



Chair's invitation

On behalf of the faculty, I am pleased to invite you to the Pfizer Oncology satellite symposium '**EGFR+, ALK+ and ROS1+ NSCLC: More options, right choices**'.

As the range of targeted therapies available for oncogene-driven non-small cell lung cancer (NSCLC) continues to grow, physicians need to adjust to a rapidly changing landscape in order to select the best treatment option for each individual patient.

During the symposium, our distinguished faculty will review how the treatment algorithms have evolved for patients with advanced EGFR+, ALK+ and ROS1+ NSCLC, and illustrate how treatment paradigms are rapidly shifting using their real-world experiences and case studies.

Finally, the faculty will discuss and share perspectives on some of the key criteria and factors that need to be considered to inform treatment decisions in routine clinical practice.

My colleagues and I look forward to welcoming you for what promises to be an interesting and engaging symposium.

Rosario García Campelo, Chair

Servicio de Oncología Médica, Hospital Universitario A Coruña, Spain

Programme

Chair: **Rosario García Campelo (Spain)**

13:00–13:05	Welcome and introduction	Rosario García Campelo (Spain)
13:05–13:15	More options, right choices	Rosario García Campelo (Spain)
13:15–13:40	EGFR: The dilemma of choice	Daniel Tan (Singapore)
13:40–14:10	ALK and ROS1: Sequencing our options to maximise outcomes	Benjamin Besse (France)
14:10–14:25	Panel discussion	All faculty, facilitated by Rosario García Campelo (Spain)
14:25–14:30	Summary and close	Rosario García Campelo (Spain)

Light refreshments will be served prior to the symposium



This meeting is organised and funded by Pfizer.
© 2019 Pfizer Pharma GmbH. All rights reserved.
June 2019. PP-ONC-GLB-0162